表达hIFNα-2b基因重组乳杆菌治疗HSV-2感染的研究  

Application of recombinant Lactobacillus expressing human INFα-2b in the treatment of herpes simplex virus type Ⅱ infection in mice

作　　者：陈辉[1] 张力平[1] 贾润清[2] 傅晓丽 姚立红[4] 陈爱君[4] 康白[5] 袁杰利[5] 张智清[4] 

机构地区：[1]首都医科大学病原生物学系,北京100069 [2]内蒙古医学院生化教研室 [3]美国Symbigene公司 [4]中国疾病预防控制中心病毒病预防控制所病毒基因工程国家重点实验室 [5]大连医科大学微生态研究所

出　　处：《中华实验和临床病毒学杂志》2006年第4期324-326,共3页Chinese Journal of Experimental and Clinical Virology

基　　金：美国Symbigene公司资助.

摘　　要：目的探讨表达人干扰素α-2b的重组乳杆菌应用于阴道HSV-2感染的治疗作用。方法建立阴道感染HSV-2的小鼠模型,使用重组菌菌液于感染前24h进行预防,或感染后48h进行治疗,记录病损程度并检测小鼠阴道分泌物中HSV-2滴度。结果使用重组菌预防或治疗的小鼠症状轻且病程缩短,病灶中病毒滴度下降很快。结论表达IFNα-2b的重组乳杆菌具有较强的局部抗病毒作用,可用于预防及治疗由HSV-2感染引起的生殖器疱疹。Objective To characterize the effect of the recombinant Lawtobacillus secreting huIFNa-2b for the treatment of HSV-2 infection. Methods The mice vaginal HSV-2 infection models were established. The mice in prevention group were treated locally with the recombinant Lactobacillus 24 hours before HSV-2 infection. Treatment group were treated with the Lawtobacillus 48 hours after HSV-2 infection. The lesion scores of mice were recorded and the virus titer in the vaginal secretion were tested. Results The symptoms of the mice in the prevention group and the treatment group were alleviated and the virus titer was dropped very quickly. Conclusion The recombinant lactobacillus DM8909/pSC-IFNa-2b might be useful in prevention and therapy of genital herpes simplex virus type Ⅱ infection.

关 键 词：干扰素Α-2B 乳杆菌属 单纯疱疹病毒属 阴道炎 

分 类 号：R96[医药卫生—药理学]